Evidence map›Paper›PMID 37368273›Full record

ReviewNanomaterials (Basel, Switzerland)2023

Smart Radiotherapy Biomaterials for Image-Guided In Situ Cancer Vaccination.

Victoria Ainsworth, Michele Moreau, Romy Guthier, Ysaac Zegeye, David Kozono, William Swanson, Marian Jandel, Philmo Oh, Harry Quon, Robert F Hobbs and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Democratizing FLASH Radiotherapy.Seminars in radiation oncology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Victoria AinsworthDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21201, USA.
Michele MoreauDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21201, USA.ORCID 0000-0002-6881-6300
Romy GuthierDepartment of Physics, Medical Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA.ORCID 0000-0002-3887-8914
Ysaac ZegeyeDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
David KozonoDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
William SwansonDepartment of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.ORCID 0000-0001-5388-4688
Marian JandelDepartment of Physics, Medical Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA.
Philmo OhNanoCan Therapeutics Corporation, Princeton, NJ 08540, USA.
Harry QuonDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21201, USA.
Robert F HobbsDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21201, USA.
Sayeda Yasmin-KarimDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Erno SajoDepartment of Physics, Medical Physics, University of Massachusetts Lowell, Lowell, MA 01854, USA.ORCID 0000-0001-6802-0014
Wilfred NgwaDepartment of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, MD 21201, USA.

Funding

Biomaterial Drones for Image-Guided Drug Delivery during radiotherapyR01CA239042 · NCI · JOHNS HOPKINS UNIVERSITY · PI NGWA, WILFRED · 2019 to 2023
$3.2M
NCI NIH HHS R01 CA239042NIH HHS R01CA239042
6 · The paper itself

Abstract

Recent studies have highlighted the potential of smart radiotherapy biomaterials (SRBs) for combining radiotherapy and immunotherapy. These SRBs include smart fiducial markers and smart nanoparticles made with high atomic number materials that can provide requisite image contrast during radiotherapy, increase tumor immunogenicity, and provide sustained local delivery of immunotherapy. Here, we review the state-of-the-art in this area of research, the challenges and opportunities, with a focus on in situ vaccination to expand the role of radiotherapy in the treatment of both local and metastatic disease. A roadmap for clinical translation is outlined with a focus on specific cancers where such an approach is readily translatable or will have the highest impact. The potential of FLASH radiotherapy to synergize with SRBs is discussed including prospects for using SRBs in place of currently used inert radiotherapy biomaterials such as fiducial markers, or spacers. While the bulk of this review focuses on the last decade, in some cases, relevant foundational work extends as far back as the last two and half decades.

Indexed as

abscopal effectcancerimage-guided radiotherapyin situ vaccinationradio-immunotherapysmart radiotherapy biomaterials

Identifiers

PMID37368273
PMCPMC10303169

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.